FDA Switch Strategy May Need Retooling To Handle Chronic Drugs
This article was originally published in The Tan Sheet
Executive Summary
The ongoing OTC statins debate highlights a need for FDA advisors to consider the societal impact of a drug therapy when evaluating Rx-to-OTC switch candidates, according to NDAC Chair Alastair Wood